Study details
Enrolling now
PTX-912 Clinical Trial
Proviva Therapeutics, Inc.
NCT IDNCT06190886ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
26
Study length
about 2.1 years
Ages
18+
Locations
3 sites in CA, FL, NE
What this study is about
This trial is testing the safety and how well PTX-912 works in people with advanced or metastatic solid tumors. The goal is to determine a safe dose of PTX-912, understand its effects on the body (pharmacokinetics), and see if it has any anti-cancer activity.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take PTX-912
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: DLTs (dose limiting toxicity)
Body systems
Oncology